An Intelligent Pressure and Temperature Control Ureteral Soft Scope System for Treating Stones With Infection.

This study protocol describes a multi-center, prospective, randomized controlled trial with a non-inferiority design, aiming to assess the efficacy and safety of an intelligent pressure and temperature-controlled ureteroscope system for treating renal and upper ureteral stones with concurrent infection. A total of 288 patients will be randomized into two groups (1:1 ratio), with the intervention group receiving the intelligent system and the control group undergoing standard ureteroscopy. The primary endpoints are the complication rate and stone clearance rate at 1 month postoperatively, while secondary endpoints include short-term stone clearance, intraoperative and postoperative complications, infection markers, surgical time, and intraoperative pressure and temperature monitoring. The study will adhere to rigorous ethical standards and statistical analysis plans to provide robust evidence for the clinical application of this novel device.

Inclusion criteria

• 18 ≤ Age ≤ 75 years old, regardless of gender, able to tolerate surgery;
• ASA I-III;
• Patients who have been confirmed by bilateral renal/urinary tract CT to have upper ureteral or renal stones, single or multiple, with a cumulative maximum diameter of 10mm < cumulative maximum diameter ≤ 20mm, and are planning to undergo ureteroscopic lithotripsy for stone removal;
• Confirmed urinary tract infection, indicated by positive urine leukocytes and nitrite, or positive urine culture, with appropriate antibiotic treatment administered preoperatively;
• Those who voluntarily participate and sign an informed consent form.

Exclusion criteria

• Uncontrollable systemic hemorrhagic disease;
• Severe spinal deformities, severe hip joint deformities, and difficulty in lithotomy position;
• Uncontrolled acute urinary tract infections;
• Any intracavitary surgery caused by anatomical factors of the urinary system cannot be performed;
• Pregnant, planned pregnancy within 3 months, and lactating female patients;
• The patients determined by the investigator to be unsuitable for this study include (but are not limited to): known to have human immunodeficiency virus (HIV) or AIDS; Suffering from mental illness; Infectious diseases.